ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

NSABP’s Pink Sheet; Fisher’s Control Had A Downside, Review Said

June 24, 1994

Five Proposals Submitted In Recompetition Of FCRF Operations/Support Contract; Now Under Review

January 2, 1987

(8-page issue).

January 31, 2003

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

April 2, 1999

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

Nevins Retracts Key Paper By Duke Group, Raising Question Of Harm To Patients

October 29, 2010